Investors

News Release

Sign up for email alerts to receive company and investor updates

Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference

Jun 17 2015

BERKELEY HEIGHTS, N.J., June 17, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the Company will present at the 10th Annual JMP Securities Healthcare Conference being held at The St. Regis New York, New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 1:30 p.m. Eastern time on Wednesday, June 24, 2015. 

Cyclacel's presentation will be webcast live and archived for 90 days on the Corporate Presentations page of the Cyclacel website at www.cyclacel.com.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor, with potential utility in both hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for more information.

(C) Copyright 2015 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

CONTACT: Contacts for Cyclacel Pharmaceuticals, Inc.



         Company: Paul McBarron, 

         (908) 517-7330, pmcbarron@cyclacel.com

         Investor Relations: Russo Partners LLC, Robert Flamm, 

         (212) 845-4226, robert.flamm@russopartnersllc.com